Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Lenvatinib (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
  • Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms LEAP-014
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 24 Oct 2023 Results (At data cut-off February 2, 2023, n=13 ) from part 1 safety run-in cohort, presented at the 48th European Society for Medical Oncology Congress
    • 11 Oct 2023 According to an Eisai Co Ltd media release, the company will present safety run-in results during the European Society for Medical Oncology (ESMO) Congress 2023, which is taking place virtually and in-person in Madrid, Spain from October 20 to 24.
    • 02 Jul 2022 Study design presented at the 24th World Congress on Gastrointestinal Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top